NEWS

Create a better world with artificial intelligence technology

Post Details
KCL medical foundation and AIDOT, leading the domestic cervical cancer diagnostic market with AI cervical cancer solution
aidot (ip:)
  • Rate 0points  
  • Date 2021-08-06
  • Recommend Recommend
  • View 172

[View original text]


 

Korea KCL Medical Foundation (Chairman Seong-ho Kim) is the only one that has been approved for a 'Class 3' clinical trial plan by the Ministry of Food and Drug Safety. After signing a contract to exclusively supply colposcope cameras in Korea, the full-fledged domestic commercialization process began.

 

The Korea KCL Medical Foundation is a mid-sized medical foundation that ranks 1st in Korea in terms of cervical cancer screening based on cytology and HPV testing, and ranks 6th 

in Korea when other tests such as diagnostic pathology and molecular diagnosis are included. As of 2021, among 3,500 hospitals in Korea, there are about 1,500 hospitals that 

conduct cervical cancer cytology and HPV tests.

 

Under this contract, Korea KCL Medical Foundation will provide cervical cancer colposcopy tests upgraded with next-generation portable colloscopic equipment based on optical lenses developed with AIDOT.

 

Currently, in the field of cervical cancer in Korea, Cerviray AI is the only one conducting a 'Class 3' clinical trial by the Ministry of Food and Drug Safety. AIDOT plans to introduce a total cervical cancer screening solution officially combined with artificial intelligence as soon as it has obtained certification from the Ministry of Food and Drug Safety.

 

In this way, primary and secondary obstetrics and gynecology hospitals can choose examinations that satisfy both hospitals and patients at a more reasonable cost than before.

 

Seong-ho Kim, Chairman of the Korea KCL Medical Foundation said, "AIDOT is the only place that has a systematic solution to conduct 'Class 3' clinical trials with artificial intelligence for cervical cancer along with IRB certification. We appreciated the possibility of this and completed not only strategic investment but also exclusive contract, and we will do our best 

to contribute to the domestic cervical cancer eradication and early diagnosis market by combining AIDOT's technology and KCL Medical Foundation's cervical cancer screening 

know-how."

 

20th. Jul. 2021. / Artificial Intelligence Newspaper / Reporter Mi-joon Jeon

 




Password Please enter your password to remove or edit this message.
Edit Comment

Password :

/ byte

Password : Submit Cancel

Add Comment
Add a commentName : Password : View Reply

Combination in 10-16 characters containing at least two of the followings: upper and lower case letters/numbers/special letters

/ byte

Please type without any spaces. (case sensitive)

Comments can be added by Member only

AIDOT

© 2020 AIDOT. All rights reserved.

WORLD SHIPPING

PLEASE SELECT THE DESTINATION COUNTRY AND LANGUAGE :

GO
close